Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (PAH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bellerophon ( Bellerophon Pulse Technologies )
ClinicalTrials.gov Identifier:
NCT01457781
First received: October 12, 2011
Last updated: August 2, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2016
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: January 30, 2015